

IMMUNOGEN INC
Form 4
April 17, 2007

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | |
|---|---------|----------|---|---|
| 1. Name and Address of Reporting Person * BLATTLER WALTER | | | 2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Executive Vice President / Former Executive VP |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 04/13/2007 | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |
| C/O IMMUNOGEN, INC., 128 SIDNEY STREET (Street) | | | 4. If Amendment, Date Original Filed (Month/Day/Year) | |
| CAMBRIDGE, MA 02139 (City) (State) (Zip) | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Code | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|---------|---|---|------------|---|--|-----------------------------------|
| | | | Code | V | Amount | (A) or (D) | | | |
| Common Stock | 04/13/2007 | | S | | 1,000 | D | \$ 5.88 | 147,400 | D |
| Common Stock | 04/13/2007 | | S | | 1,300 | D | \$ 5.89 | 146,100 | D |
| Common Stock | 04/13/2007 | | S | | 2,500 | D | \$ 5.9 | 143,600 | D |
| Common Stock | 04/13/2007 | | S | | 1,200 | D | \$ 5.91 | 142,400 | D |
| Common Stock | 04/13/2007 | | S | | 1,700 | D | \$ 5.92 | 140,700 | D |

Edgar Filing: IMMUNOGEN INC - Form 4

| | | | | | | | |
|--------------|------------|---|-------|---|---------|---------|---|
| Common Stock | 04/13/2007 | S | 600 | D | \$ 5.93 | 140,100 | D |
| Common Stock | 04/13/2007 | S | 2,200 | D | \$ 5.94 | 137,900 | D |
| Common Stock | 04/13/2007 | S | 1,800 | D | \$ 5.95 | 136,100 | D |
| Common Stock | 04/13/2007 | S | 200 | D | \$ 5.96 | 135,900 | D |
| Common Stock | 04/13/2007 | S | 2,100 | D | \$ 5.97 | 133,800 | D |
| Common Stock | 04/13/2007 | S | 1,800 | D | \$ 5.98 | 132,000 | D |
| Common Stock | 04/13/2007 | S | 3,000 | D | \$ 6 | 129,000 | D |
| Common Stock | 04/13/2007 | S | 1,900 | D | \$ 6.01 | 127,100 | D |
| Common Stock | 04/13/2007 | S | 300 | D | \$ 6.02 | 126,800 | D |
| Common Stock | 04/13/2007 | S | 1,300 | D | \$ 6.03 | 125,500 | D |
| Common Stock | 04/13/2007 | S | 600 | D | \$ 6.05 | 124,900 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned (Instr. 6) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|--------------------------|---------------------------|
| | Director | 10% Owner | Officer | Other |
| BLATTLER WALTER C/O IMMUNOGEN, INC. 128 SIDNEY STREET CAMBRIDGE, MA 02139 | | | Executive Vice President | Former Executive VP |

Signatures

/s/ Walter
Blattler

04/17/2007

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.